

Virtual Mentor

Ethics Journal of the American Medical Association

November 2005, Volume 7, Number 11

Suggested Readings and Resources

November 2005

Agency for Healthcare Research and Quality. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects. Available at: <http://www.ahrq.gov/clinic/epcsums/ephedsum.pdf>. Accessed October 27, 2005.

Allen DB, Fost N. hGH for short stature: ethical issues raised by expanded access. *J Pediatr*. 2004;144:648-652.

American Academy of Pediatrics Committee on Drugs and Committee on Bioethics. Considerations related to the use of recombinant human growth hormone in children. *Pediatrics*. 1997;99:122-129.

American Academy of Pediatrics Policy Statement. Evaluation of the newborn with developmental anomalies of the external genitalia. *Pediatrics*. 2000;106:138-142.

American College of Obstetricians and Gynecologists Women's Health Care Physicians. Executive summary. Hormone therapy. *Obstet Gynecol*. 2004;104:1S-4S.

American Medical Association Council on Scientific Affairs. *Report 4 Recommendations for Physician and Community Collaboration on the Management of Obesity*. Annual Meeting, 2005. Available at: <http://www.ama-assn.org/ama/pub/category/15495.html> Accessed October 24, 2005.

American Medical Association Council on Scientific Affairs. *Report 6 Obesity as a Major Public Health Program*. AMA Annual Meeting, 1999. Available at: <http://www.ama-assn.org/ama1/pub/upload/mm/443/csaa-99.pdf>. Accessed October 24, 2005.

American Medical Association. *H-160.938 Disease-Specific Self-Management Programs*. AMA Interim Meeting, 1996. Amended by CSA Report 4 A-98 Available at: http://www.ama-assn.org/apps/pf_new/pf_online?f_n=browse&doc=policyfiles/HnE/H-160.938.HTM. Accessed October 24, 2005.

American Medical Association House of Delegates. *Resolution 405 Recognizing and Taking Action in Response to the Obesity Crisis*. Annual Meeting, 2003, re-affirmed Annual Meeting, 2004. Available at: http://www.ama-assn.org/apps/pf_new/pf_online?f_n=browse&doc=policyfiles/DIR/D-440.980.HTM. Accessed October 24, 2005.

Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA*. 2004;291:1701-1712.

Barker DJ, Eriksson JG, Forsen T, Osmond C. Infant growth and income 50 years later. *Arch Dis Child*. 2005;90:272-273.

Beers MH, Berkow R, eds. *The Merck Manual of Diagnosis and Therapy*. Available at: www.merck.com/mrkshared/mmanual/section2/chapter13/13b.jsp. Accessed September 30, 2005.

Berger M. Chronically diseased patients and their doctors. *Med Teach*. 2002;24:642-644.

Brock D. Growth hormone treatment: summing up the issues. *Endocrinologist*. 2001;11:83S-91S.

Buchanan A. Growth hormone: a paradigm of expansive biotechnologies. *Endocrinologist*. 2001;11:78S-82S.

Carel JC, Ecosse E, Bastie-Sigeac I, et al. Quality of life determinants in young women with Turner's syndrome after growth hormone treatment: results of the StaTur population-based cohort study. *J Clin Endocrinol Metab*. 2005;90:1992-1997.

Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. *J Pediatr*. 2004;145:744-749.

Cassidy SB. Prader-Willi syndrome in the new millennium. *Endocrinologist*. 2001;10(suppl 1):1S-73S.

Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA*. 2003;290:1729-1738.

Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. *N Engl J Med*. 2004;350:991-1004.

Conner v Ofreneo, 257 Ill. App.3d 427, 436 (1993).

Conway B, Rene A. Obesity as a disease: no lightweight matter. The International Association for the Study of Obesity. *Obes Rev*. 2004;5:145-151.

Cuttler L. Editorial: safety and efficacy of growth hormone treatment for idiopathic short stature. *J Endocrinol Metab*. 2005;90:5502-5504.

Department of Health and Human Services. *The Surgeon General's Call to Action to Prevent Overweight and Obesity 2001*. Available at:

www.cdc.gov/nccdphp/dnpa/pdf/calltoaction.pdf Accessed November 1, 2005.

Dhar R, Stout CW, Link MS, Homoud MK, Weinstock J, Estes NA 3rd. Cardiovascular toxicities of performance-enhancing substances in sports. *Mayo Clinic Proc* 2005;80:1307-1315.

Diamond M, Sigmundson HK. Management of intersexuality. Guidelines for dealing with persons with ambiguous genitalia. *Arch Pediatr Adolesc Med*. 1997;151:1046-1050.

Diekema DS. Is maximizing height good parenting? *Endocrinologist*. 2001;11(4, Suppl 1):67S-71S.

Edelstein L. *The Hippocratic Oath: Text, Translation, and Interpretation*. Baltimore, Md: Johns Hopkins Press; 1943.

Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. *Obstet Gynecol*. 2004;104:443-451.

Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L. Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. *Arch Pediatr Adolesc Med*. 2002;156:230-240.

Finkelstein BS, Singh J, Silvers JB, Marrero U, Neuhauser D, Cuttler L. Patient attitudes and preferences regarding treatment: GH therapy for childhood short stature. *Horm Res*. 1999;51(Suppl 1):67-72.

Food and Drug Administration. Guidance for Industry. *Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms—Recommendations for Clinical Evaluation*. Available at: <http://www.fda.gov/cder/guidance/5412dft.doc>. Accessed October 31, 2005.

Fost N. Banning drugs in sports: a skeptical view. *Hastings Cent Rep*. 1986;16:5-10.

Fost N. "I was like—whoa": a commentary on Shapiro's performance enhancement and the control of attributes. *South Calif Law Rev*. 1991;65:115-120.

Fost N. Steroids are only fair. *Newsday*. Feb 29, 2004: A56.

Fost N. What's wrong with performance enhancing drugs? *Virtual Mentor*. July 2004. Available at www.ama-assn.org/ama/pub/category/12613/html. Accessed October 31, 2005.

Gianakos D. Pounds. *Ann Fam Med*. 2004;2:366-367.

- Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. *Obstet Gynecol.* 2003;101:337-345.
- Hensley WE. Height as a basis for interpersonal attraction. *Adolescence.* 1994;29:469-474.
- Heshka S, Allison DB. Is obesity a disease? *Int J Obesity.* 2001;25:1401-1404.
- Hintz R, Attie K, Baptista J, Roche A. Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group. *N Engl J Med.* 1999;340:502-507.
- Hoffman RP. Adolescent adherence in type 1 diabetes. *Comp Ther.* 2002;28:128-133.
- Jauhar S. Give up? No way. On a matter of life or death, a patient is overruled. *New York Times.* Oct 5, 2004: F5.
- Keltner D, Capps L, Kring AM, Young RC, Heerey EA. Just teasing: a conceptual analysis and empirical review. *Psychol Bull.* 2001;127:229-248.
- Kemp SF, Kuntze J, Attie KM, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. *J Clin Endocrinol Metab.* 2005;90:5247-5253.
- Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. *Obstet Gynecol.* 2004;104:824-836.
- Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. *Ann Intern Med.* 2002;137:805-813.
- Lantos J, Siegler M, Cuttler L. Ethical issues in growth hormone therapy. *JAMA.* 1989;261:1020-1024.
- Lee PR. Health system reform and the generalist physician. *Acad Med.* 1995;70:S10-S13.
- Levetan CS, Jablonski KA, Passaro MD, Ratner RE. Effect of physician specialty on outcomes in diabetic ketoacidosis. *Diabetes Care.* 1999;22:1790-1795.
- Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. *JAMA.* 2002;287:2668-2676.
- Loprinzi CL, Barton DL, Rhodes D. Management of hot flashes in breast-cancer survivors. *Lancet Oncol.* 2001;2:199-204.

Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med.* 2003;349:523-534.

Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. *J Clin Endocrinol Metab.* 2000;85:3653-3660.

Medical Society of the State of New York. *Resolution 421.* AMA Annual Meeting, 2004. Available at: <http://www.ama-assn.org/meetings/public/annual04/421a04.doc>. Accessed October 24, 2005.

Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. *Med Sci Sports Exerc.* 1995;27:1252-1262.

Melo KF, Mendonca BB, Billerbeck AE, et al. Clinical, hormonal, behavioral, and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene. *J Clin Endocrinol Metab.* 2003;88:3241-3250.

Migeon CJ, Wisniewski AB, Gearhart JP, et al. Ambiguous genitalia with perineoscrotal hypospadias in 46,XY individuals: long-term medical, surgical, and psychosexual outcome. *Pediatrics.* 2002;110:e31. Available at: <http://pediatrics.aappublications.org/cgi/content/full/110/3/e32>. Accessed October 27, 2005.

National Institutes of Health. *Statement on Management of Menopause-Related Symptom.* NIH Consensus Development Program. NIH State-of-the-Science Conference, March 21-23, 2005.

North American Menopause Society. Amended report from the NAMS Advisory Panel on postmenopausal hormone therapy. *Menopause.* 2003;10:6-12.

North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. *Menopause.* 2004;11:11-33.

Parens E, ed. *Enhancing Human Traits: Ethical and Social Implications.* Washington, DC: Georgetown University Press; 1998.

Pauly M. Access to growth hormone therapy: an economist's perspective. *Endocrinologist.* 2001;11(4, Suppl 1):47S-55S.

Peeters A, Barendregt JJ, Willekens F, Mackeback JP, Al Mamun A, Bonneus L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. *Ann Intern Med.* 2003;138:24-38.

Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. *Fertil Steril*. 2003;80:1234-1240.

Polo-Kantola P, Erkkola R, Helenius H, Irjala K, Polo O. When does estrogen replacement therapy improve sleep quality? *Am J Obstet Gynecol*. 1998;178:1002-1009.

Quigley CA, Gill AM, Crowe BJ, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. *J Clin Endocrinol Metab*. 2005;90:5188-5196.

Quigley CA, Tan JA, He B, et al. Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction. *Mech Ageing Dev*. 2004;125:683-695.

Reiter EO, Rosenfeld RG. Normal and aberrant growth. In: Larsen RP, Kronenberg HM, Melmed S, Polonsky KS, eds. *Williams Textbook of Endocrinology*. Philadelphia, Pa: Saunders; 2003:1003-1114.

Rosenfeld RG. Is growth hormone deficiency a viable diagnosis? *J Clin Endocrinol Metab*. 1997;82:349-351.

Ross JL, Sandberg DE, Rose SR, et al. Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. *J Clin Endocrinol Metab*. 2004;89:4873-4878.

Saenger P, Attie KM, DiMartino-Nardi JW. Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Group. *J Clin Endocrinol Metab*. 1998;83:3115-3120.

Sandberg DE, Brook AE, Campos SP. Short stature: a psychosocial burden requiring growth hormone therapy? *Pediatrics*. 1994;94:832-840.

Sandberg DE, Bukowski WM, Fung CM, Noll RB. Height and social adjustment: are extremes a cause for concern and action? *Pediatrics*. 2004;114:744-750.

Sandberg DE, Colman M, Voss LD. Short stature and quality of life: a review of assumptions and evidence. In: Pescovitz OH, Eugster E, eds. *Pediatric Endocrinology: Mechanisms, Manifestations, and Management*. Philadelphia, Pa: Lippincourt, Williams & Wilkins; 2004:191-202.

Sandberg DE, Michael P. Psychosocial stresses related to short stature: does their presence imply psychiatric dysfunction? In: Drotar D, ed. *Assessing Pediatric Health-Related Quality of Life and Functional Status: Implications for Research*. Mahwah, NJ: Lawrence Erlbaum Associates; 1998:287-312.

Sandberg DE, Voss LD. The psychosocial consequences of short stature: a review of the evidence. *Best Pract Res Clin Endocrinol Metab.* 2002;16:449-463.

Shah N. Taking a history: introduction and the presenting complaint. *Student BMJ.* 2005;13:314-315.

Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA.* 2004;291:2947-2958.

Slyper A. The safety and effectiveness of human growth hormone using pharmacological dosing. *Med Hypotheses.* 1995;45:523-528.

Smith H. A model for validating an expert's opinion in medical negligence cases. *J Leg Med.* 2005;26:207-231.

Tauer CA. The NIH trials of growth hormone for short stature. *IRB.* 1994;16:1-9.

Theunissen NC, Kamp GA, Koopman HM, Zwinderman KA, Vogels T, Wit JM. Quality of life and self-esteem in children treated for idiopathic short stature. *J Pediatr.* 2002;140:507-515.

Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. *Fertil Steril.* 2001;75:1065-1079.

Vance ML, Mauras N. Growth hormone therapy in adults and children. *New Engl J Med.* 1999;341:1206-1216.

Voss LD, Sandberg DE. The psychological burden of short stature: evidence against. *Eur J Endocrinol.* 2004;151 Suppl 1:S29-33.

Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative randomized trial. *JAMA.* 2003;289:2673-2684.

Wit JM, Rekers-Mombarg LT, Cutler GB, et al. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. *J Pediatr.* 2005;146:45-53.

World Anti-Doping Agency. *World Anti-Doping Code*. Available at: http://www.wada-ama.org/rtecontent/document/code_v3.pdf. Accessed October 27, 2005.

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. *JAMA.* 2002;288:321-333.

Wysocki T, Taylor A, Hough BS, Linscheid TR, Yeates KO, Naglieri JA. Deviation from developmentally appropriate self-care autonomy. Association with diabetes outcomes. *Diabetes Care*. 1996;19:119-125.

Yesalis CE, ed. *Anabolic Steroids in Sport and Exercise*. 2nd ed. Champaign, Ill: Human Kinetics Press; 2000.

Zimet GD, Cutler M, Litvene M, Dahms W, Owens R, Cuttler L. Psychological adjustment of children evaluated for short stature: a preliminary report. *J Dev Behav Pediatr*. 1995;16:264-270.

The viewpoints expressed on this site are those of the authors and do not necessarily reflect the views and policies of the AMA.

Copyright 2005 American Medical Association. All rights reserved.